Grifols' top line has stabilized, with revenue growth of 9.4% year over year in 2026Q3 and gross margin recovering from 34.7% in 2025Q4 to 40.1%, though this rebound has not yet proven durable.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth reaccelerated to 9.4% year over year in 2026Q3 and operating margin expanded from 14.6% in 2026Q1 to 21.0%, though the gap to a 9.3% net margin warrants scrutiny of below-the-line items.
Grifols is a global healthcare leader with a long history of innovation and commitment to improving health and well-being.
The company specializes in plasma-derived medicines and biopharmaceuticals, serving millions of patients worldwide.
Grifols has a rare and durable competitive moat due to its clinical self-sufficiency, exemplified by its integrated model in Egypt.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 2, 2026 | $0.34+4.9% vs $0.32 | $2.3B+3.3% vs $2.2B |
Q3 2026 Jul 28, 2026 | $0.25-7.0% vs $0.27 | $2.1B-1.5% vs $2.2B |
Q2 2026 May 7, 2026 | $0.17+7.3% vs $0.16 | $2.0B-1.4% vs $2.0B |
Q1 2026 Feb 26, 2026 | $0.29-0.3% vs $0.29 | $2.3B-0.2% vs $2.3B |
Grifols remains a speculative 'BUY' with a €20/share price target, offering over 20% annual upside if growth continues. GIKLY has delivered strong 3Q26 results: revenue above €2B quarterly, EBITDA up 10%, net profit up 28%, and leverage now below 4x. Strategic expansion into Egypt is expected to diversify plasma sourcing, reduce costs, and support margin improvement through geographic diversification.
Grifols, S.A. (GIKLY) Q3 2026 Earnings Call Transcript
Grifols NASDAQ: GRFS reported third-quarter 2026 results marked by revenue growth, expanding profitability, stronger free cash flow and lower leverage, while management reiterated its full-year financial targets despite continued weakness in China's albumin market.
Grifols, S.A. (NASDAQ: GRFS - Get Free Report) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totaling 7,001,241 shares, a growth of 105.0% from the September 15th total of 3,414,455 shares. Based on an average daily volume of 808,104 shares, the days-to-cover ratio is
Benchmark GRFS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Grifols, S.A. (GRFS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.43 | $7.13B | 10.00 | 0.2% | 6.77% | 6.5% | 2.39% | |
| $21.02 | $66.87B | 27.66 | 4.28% | 8.16% | 5.08% | 2.92% | |
| $375.74 | $15.2B | 20.71 | 0.33% | 13.78% | 44.18% | 1.12% | |
| $14.48 | $2.18B | -4.03 | — | — | -2271.87% | — | |
| $12.50 | $1.1B | 26.07 | 420.21% | 20.88% | 2.98% | 13.77% | |
| $7.69 | $1.95B | -5.72 | 94.1% | -37.41% | — | — |
Grifols, S.A. (GRFS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when GRFS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Grifols, S.A. (GRFS) stock FAQ — growth, dividends, profitability & financials explained
Grifols, S.A. (GRFS) reported $7.61B in revenue over the trailing twelve months. Revenue was $7.23B in fiscal year 2025. That is 1278% more than the $524.3M of fiscal year 2005.
Grifols, S.A. (GRFS) grew revenue by 1.2% over the trailing twelve months, compared with the twelve months before.
Yes. Grifols, S.A. (GRFS) earned $514.5M in net income over the trailing twelve months (a 6.8% net margin).
Yes. Grifols, S.A. (GRFS) pays a dividend that yields 2.39% at the current price, a moderate yield.
Grifols, S.A. (GRFS) had a return on equity (ROE) of 6.5% over the trailing twelve months. That is below the market's typical 10-15%.
Grifols, S.A. (GRFS) generated $746.7M in free cash flow over the trailing twelve months.
